The Venture Letter™’s Post

The Venture Letter™ - Update Report on XORTX Therapeutics Inc.  (NASDAQ: XRTX / TSXV: XRTX / Frankfurt: ANUA) - I am pleased to provide interested investors with an update report on XORTX Therapeutics Inc. Since the beginning of 2024, there have been numerous multi-billion dollar, biotech buyouts that must be considered when considering becoming a shareholder in XORTX. Good luck and good hunting. #XORTX #TheVentureLetter #Biotechs #Buyouts #NASDAQ #TSXV #Biotechstocks #Stockmarkets #kidneydisease #orphandrugs

𝗟𝗼𝗻𝗴-𝗧𝗲𝗿𝗺 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗔𝗱𝘃𝗶𝗰𝗲 💡 Corcept Therapeutics (NASDAQ: CORT) is on the rise! 🚀 - 𝗠𝗮𝗿𝗸𝗲𝘁 𝗖𝗮𝗽 𝗼𝗳 $𝟰.𝟰𝟮 𝗕𝗶𝗹𝗹𝗶𝗼𝗻 - 𝟰𝟲.𝟮% 𝘀𝘁𝗼𝗰𝗸 𝘀𝘂𝗿𝗴𝗲 - $𝟯𝟭𝟬.𝟲𝗠 𝗶𝗻 𝘀𝗮𝗹𝗲𝘀 𝗳𝗼𝗿 𝗞𝗼𝗿𝗹𝘆𝗺 Exciting developments ahead! 🌟 Read full analysis and investment details on our website. Link in the comment! #biotech #investing #HealthcareInnovation #StockMarket #NASDAQ

Esperion Therapeutics (NASDAQ: ESPR) Stock Jumps on Upbeat Q1 Financial Report https://lnkd.in/dgvfr3rW $ESPR #Esperion #NASDAQ #stockmarket #stockmarketnews #BusinessNews #news #NewsAlert

March 28 and April 01, 2024 headlines from the Collabrity Report, a daily summary of financings for therapeutic biotechnology company executives and investors - www.collabrityreport.com Surrozen’s $192 Million Private Placement Teva’s $150 Million Royalty Financing Contineum’s $150 Million IPO BioLineRx’s $6 Million Registered Direct Offering Biora’s $6 Million Registered Direct Offering Praxis’s $200 Million Public Offering CervoMed’s $149 Million Private Placement Boundless’s $100 Million IPO Aeovian’s $50 Million Series A NervGen’s $23 Million Public Offering Xilio’s $11 Million Private Placement Molecular’s $10 Million Private Placement Tonix’s $4 Million Registered Direct Offering

March 28 and April 01, 2024 headlines from the Collabrity Report, a daily summary of financings for therapeutic biotechnology company executives and investors - www.collabrityreport.com Surrozen’s $192 Million Private Placement Teva’s $150 Million Royalty Financing Contineum’s $150 Million IPO BioLineRx’s $6 Million Registered Direct Offering Biora’s $6 Million Registered Direct Offering Praxis’s $200 Million Public Offering CervoMed’s $149 Million Private Placement Boundless’s $100 Million IPO Aeovian’s $50 Million Series A NervGen’s $23 Million Public Offering Xilio’s $11 Million Private Placement Molecular’s $10 Million Private Placement Tonix’s $4 Million Registered Direct Offering

Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) is seeking to relist its stocks on the #Nasdaq with a re-domiciliation to the United States under a scheme of arrangement that would see Delaware-based Anteris Technologies Global Corp become the parent company of the Anteris Group. The new holding company would then seek a listing on the Nasdaq – alongside a secondary listing of its CDIs on the ASX – and undertake an initial public offering (IPO) targeted at, but not restricted to, US investors. AVR plans to complete the relisting and the IPO by the end of 2024, targeting between US$75 million and US$100 million. More at #Proactive #ProactiveInvestors #NasdaqListing #IPO #Biotech #Biopharmaceutcials #MedicalDevices http://ow.ly/PxuI105FeNJ

🎉Congratulations from Checkmate Equity🎉 💼Company: Attovia Therapeutics💰#Funding: $105Million⚡Round: Series B 👥Investors: Goldman Sachs Alternatives, Cormorant Asset Management, LP, Nextech Ventures, Redmile Group, EcoR1 Capital, LLC, Marshall Wace, and Logos Capital. Attovia is creating a pipeline of biotherapeutics with an initial focus on immune-mediated diseases. The company leverages ATTOBODY™, a biparatopic biologics platform, to generate binders that offer stronger efficacy and a broader universe of druggable epitopes compared to traditional approaches. 🚀OFFLOAD YOUR CAP TABLE MANAGEMENT TASKS TODAY🎉 Checkmate Equity is a trusted Carta partner with experience managing over 2,000 #captables. Our expertise ensures compliance, accuracy, and timely updates for your cap table. With a dedicated Equity Administrator, we streamline the process, ensuring rapid updates. 🚀 Tao Fu and Zaneta Odrowaz, let me know if you need assistance with the adjustments to your Cap Table. 📊

On January 11, 2024, C4 Therapeutics, Inc. (the “Company”) (NASDAQ:CCCC) posted an investor presentation to its website at https://lnkd.in/eFGCib_T. A copy of the investor presentation is furnished herewith as Exhibit 99.1. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information. https://lnkd.in/eWhCuGQv

We’re delighted to see Syntara’s Phase 2a trial in myelofibrosis featured in Livewire Markets, highlighted by Dr. Bianca Ogden and Hashan De Silva as one of "The 7 biotech stocks (and their trials) these experts are watching right now." "Positive data would build on data from the previous trial and place the company very well in a disease state with a lot of corporate activity. Acquisitions in this space are north of US$1bn which is well over 30x Syntara’s market cap." https://lnkd.in/gtfa_7EY #SNT #Syntara #Biotech #Myleofibrosis #ClinicalTrials #SyntaraCares#ASX